305 FEARS AND BELIEFS REGARDING KNEE OSTEOARTHRITIS: VIEWS FROM PATIENTS AND PRACTITIONERS. ELABORATION OF THE KNEE FEAR-BELIEF QUESTIONNAIRE (KFBQ) USING A QUALITATIVE INTERVIEW STUDY AND A DELPHI CONSENSUS METHOD  by Boutron, I. et al.
S164 Poster Presentations
Table 1. Sample description
Age M/F Urban/Rural Marital Status
Mean, sd (with partner/alone)
Group 1
(n=23) 58.7, 11.0 7/16 (30.4/69.5%) 12/11 (52.2/47.8%) 8/15 (34.8/65.2%)
Group 2
(n=49) 62.6, 9.3 9/40 (18.4/81.6%) 24/25 (49.0/51.0%) 14/35 (28.6/71.4%)
Group 3
(n=22) 63.0, 9.9 4/18 (18.2/81.8) 15/7 (68.2/31.3%) 8/14 (36.4/63.6%)
Table 2. Pain, Disability and Participation
Group 1 (n=23) Group 2 (n=49) Group 3 (n=22)
mean (95% CI) mean (95% CI) mean (95% CI)
Constant Pain 14.6 (2.1-27.0) 25.1 (17.0-33.2) 25.7 (10.2-41.1)
Intermittent Pain 29.7 (20.8-38.6) 35.8 (28.4-43.2) 47.0 (34.9-59.0)
Total Pain 22.8 (17.5-28.1) 30.9 (26.2-35.6) 37.3 (28-46.5)
NRS Pain 5.1 (4.1-6.1) 5.5 (5.0-6.1) 6.9 (5.8-7.9)
KOOS-PS 38.4 (31.0-45.7) 48.6 (45.2-52.1) 46.1 (41.1-51.1)
KOOS-ADL 68.7 (59.8-77.7) 58.1 (53.2-63.0) 56.0 (47.6-64.4)
SRPQ: Importance 3.6 (3.4-3.8) 3.6 (3.5-3.7) 3.8 (3.1-4.5)
SRPQ: Ability 3.1 (2.6-3.5) 3.1 (2.9-3.3) 2.6 (2.2-3.1)
those with early OA, 21% (5/23) intermittently used prescription
medication, 65% used over the counter medication and 22% used
glucosamine.
Conclusions: People with early OA experience pain and disability
although the trend is to a lesser degree than for those with mod-
erate and end-stage OA, as expected. A proportion of individuals
are seeking care. However, although the sample is small, these
data highlight the need for a better understanding of this subgroup
of people with early OA related to possible disease progression
and interventions to ameliorate symptoms and disability.
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Background: Results of clinical trials in OA are usually reported
as group comparisons of the mean (± standard deviation, sd) in
score of the selected outcome. It might be more clinically relevant
to show the results at a patient level, using a response criterion.
Several response criteria are available: OARSI/OMERACT modi-
ﬁed set of responder criteria [1], the Patient Acceptable Symptom
State (PASS) [2] and the Minimum Clinically Important Improve-
ment (MCII) [3].
Objectives: To assess differences in responder rates using vari-
ous response criteria in a RCT in knee OA.
Methods: Data were extracted from a prospective, multicentre,
double-blind RCT comparing two hyaluronans over 24 weeks
(F60027-Structovial and Hylan G-F 20-Synvisc) according to a
Abstract 304 – Table 1. Responder rates according to various deﬁnitions of response in a RCT in knee OA
PP dataset F60027 group Hylan G F-20 group Global population
Baseline pain score (0-100, mm) (sd) 68.6 (13.2) 67.5 (11.6) 68.1 (12.5)
Mean change from baseline at week 24 (mm) (sd) -38.8 (24.7) -37.1 (25.4) -38.0 (25.0)
N (%) of patients at PASS for pain at week 24 ≤32.3 mm 71 (59.7%) 78 (66.7%) 149 (63.1%)
N (%) of patients achieving MCII(absolute) on pain at week 24≥ 19.9 mm 96 (80.7%) 88 (75.2%) 184 (78%)
N (%) of patients achieving MCII (%) on pain at week 24 ≥40.8% improvement 83 (69.7%) 83 (70.9%) 166 (70.3%)
OMERACT/OARSI response criteria 77 (64.7%) 79 (67.5%) 156 (66%)
Baseline LFI score 13.6 (3.2) 13.2 (2.9) 13.4 (3.1)
Mean LFI score change from baseline at week 24 -5.7 (3.8) -5.6 (4.0) -5.7 (3.9)
non inferiority design. The main outcome was the Lequesne index
score (LFI). The secondary outcome was global pain on a Visual
Analog Scale (VAS). 236 patients were available in the main
analysis (per protocol analysis, PP). Demographic and knee OA
characteristics were identical to those usually reported in knee OA
trials. Since no value of the PASS is validated for the LFI yet, the
results on pain VAS were used to classify patients as responders
or not using OMERACT/OARSI modiﬁed criteria, PASS and MCII
(using absolute value or % of improvement). Results are reported
as mean (sd) and number (%).
Results: Table 1 below shows the response rates according to
the different criteria. Rates of responders varied considerably:
from 60 to 80% in each group and from 63% to 78% in the
overall population (both treatment groups can be merged since
non-inferiority was proven). The most liberal deﬁnition seems to
be MCII (absolute), while the strictest appears to be PASS.
Conclusions: Reporting clinical trial results at a patient level using
response rates might be meaningful in knee OA. However this
study clearly demonstrate that results signiﬁcantly vary according
to the response criterion used which is likely to lead to "positive"
or "negative" results accordingly. More work is needed to help
assessing the most clinically relevant response deﬁnition in knee
OA.
Acknowledgement: This work was possible thanks to a grant
from Pierre Fabre Labs.
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Purpose: Fears and beliefs of patients are well identiﬁed in low
back pain patients but not usually taken into consideration for
management strategies and their assessment in OA. To identify
fears and beliefs of patients regarding knee OA management and
to develop a questionnaire assessing fears and beliefs of patients.
Methods: A qualitative study based on semi structured interviews
was performed with a stratiﬁed sample of 81 patients (59 women)
and 29 practitioners (8 women, 11 general practitioners (GPs),
6 rheumatologists, 4 orthopedic surgeons, 8 (4 GPs) delivering
alternative medicine). Eleven independent experts analyzed the
Osteoarthritis and Cartilage Vol. 17, Supplement 1 S165
interviews and a questionnaire was developed by use of a Delphi
consensus method.
Results: Semi-structured interviews identiﬁed fears and beliefs
about the cause and factors inﬂuencing evolution of knee OA,
the impact of knee OA in daily and social life, treatments and
practitioners. Patients often belief that knee OA is an inevitable
illness associated with age and that not much can be done to
modify its evolution. They also express unrealistic fears about the
impact of knee OA on daily and social life. They often belief that
treatments are of little help and that practitioners have not much to
propose. One hundred thirty seven items were proposed from the
analysis of the qualitative study. Four Delphi rounds were needed
to propose a 24-items questionnaire assessing fears and beliefs
of patients regarding knee OA management.
Conclusions: Our results suggest several unrealistic and negative
fears and beliefs in patients with knee OA. We propose a 24-
items questionnaire to assess these fears and beliefs of patients
regarding knee OA management. This questionnaire must now be
validated.
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Purpose: Patients with osteoarthritis (OA), due to age, walking
functional impairment and/or a high prevalence of obesity, are
at a high risk of metabolic disorders and cardiovascular (CV)
comorbidities. Moreover, patients with OA are frequently treated
with NSAIDs, which could negatively inﬂuence CV disorders.
Objectives: To evaluate the frequency of metabolic disorders and
CV comorbidity in patients with symptomatic OA of knee, hip or
hands in patients seen in a rheumatology consultation in a primary
health setting.
Methods: Consecutive patients aged >50 y referred during a 6-
month period to a rheumatology practice in a primary health setting
because of OA of the knee, hip or hands. Diagnostics related to
CV comorbidity and/or glycemic or lipid disorders (hypertension,
diabetes, ischemic heart disease, heart failure, cerebrovascular
disorder, venous insufﬁciency or dyslipemia) were obtained for
each patient from the computerized data base (e-cap system)
used by their family physicians. Patients with soft tissue disorders
(e.g. shoulder tendinitis, plantar fasciitis, etc) adjusted for age were
used as control group.
Results: 290 patients were included, 160 with OA and 130 with
soft tissue disease, mean age 64.4±9.5 y, F/M 222/68 (77/23%).
No differences were found between both groups regarding age
or gender. The frequencies of hypertension and obesity were
signiﬁcantly higher in the OA group, especially in those with
knee/hip OA; dyslipemia was also statistically more frequent in
the OA group. Diabetes was more prevalent in the OA, especially
in those with lower limb arthritis but did not achieve statistical
signiﬁcance. Metabolic syndrome (diabetes/glucose intolerance
+ >2 of the following: hypertension, dyslipemia, obesity) was
signiﬁcantly more frequent in patients with OA and especially knee
OA (Table 1). Thirty-one percent of OA patients and metabolic
syndrome were on chronic NSAID treatment whereas no patient
with metabolic syndrome in the control group was being treated
with NSAID. No differences for the rest of variables were detected
between the OA and control group.
Conclusions: These data suggest that metabolic and cardiovas-
cular disorders are more prevalent in patients with OA, particularly
in patients with knee or hip OA. This fact is especially relevant
given the prevalence of OA in the population and the high rate
Table 1
OA Lower limb OA1 Knee OA Control
(n=160) (n=118) (n=97) (n=130)
% female 80 78.8 82.5 72.3
Age (years) 66±9.6 67.5±9.5 68.1±9.7 62.3±8.9
Diabetes 18.8% 20.3% 21.4% 18.6%
Hypertension 56.9%*** 63.6%* 64.9%*** 34.6%
Dyslipemia 33.8%* 32.2% 30.9% 21.5%
Obesity 23.8% 28%*** 30.9%*** 10.8%
Metabolic syn. 11.9%** 12.7%* 12.4%* 3.1%
1 Knee/hip OA. *<0.05, **<0.001, ***<0.0005 vs. control.
of NSAID therapy in these patients. More extensive poblational
studies are warranted in order to conﬁrm these results.
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Purpose: This report presents a follow up study conducted in con-
tinuance to an original double blind, prospective study which as-
sessed the effectiveness of a novel biomechanical device (APOS
system) comprising of four individually calibrated elements at-
tached onto foot-worn platforms and capable of unloading the
diseased articular surface in knee osteoarthritis (OA), and simul-
taneously train neuromuscular control by controlled perturbations.
The purpose of this study was to examine the effectiveness of the
biomechanical device in reducing pain and improving function in
knee OA patients two year following the original study.
Methods: 35 patients with knee OA volunteered to continue the
follow-up for additional 24 months. 26 of them were in the active
group and 9 patients were in the control group. Patients continued
the treatment with the device that had been individually calibrated
to accommodate a diminished-pain joint alignment and train neu-
romuscular control. Patients were assessed 12 months and 24
months after the original study ended. Primary outcome measures
were the WOMAC index and the Aggregated Locomotor Function
(ALF) assessment. Secondary outcome measures were the SF-36
health survey and the Knee Society Score.
Results: At 12 and 24 months, the active group maintained the
signiﬁcant pain relief and improved function that were obtained at
the end of the original study, showing a decrease of 3.6cm and
3.5cm, in the WOMAC-Pain subcategory, representing a mean im-
provement of 68% and 66%, after 12 and 24 months respectively
(p<0.001). Patients also showed a decrease of 3.5cm and 3.3cm,
in the WOMAC-function subcategory, representing a mean im-
provement of 69% and 65%, after 12 and 24 months respectively
(p<0.001). Patients maintained the improved ALF score after 12
and 24 months showing a decrease of 13.9 sec and 12.9 sec,
representing a mean improvement of 37% and 34%, after 12 and
24 months respectively (p<0.001).
Conclusions: The reduced pain and improved function following
a treatment with the APOS system was continuous after 12 and 24
months indicating that the APOS system and treatment method-
ology is an effective, long term, therapy for patients with knee
OA.
